Currently, active study of the targeting of the CXCL12/CXCR4/CXCR7 axis in the treatment of malignancy, rheumatoid arthritis, and multiple sclerosis is being carried out [37,38]. This evidence concerns the gene CXCL12 and rheumatoid arthritis.